Skip to content

Kodiak Sciences Inc KOD Restricted Cash

Restricted Cash at other companies

Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$0-100%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$1.61M0.0%
Immunome logo
ImmunomeIMNM
$210K+110%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$308K-50.1%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$3M0.0%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.32B+1,477%
Enterprise value$2.2B+2,798%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Reported directly by Kodiak Sciences Inc in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.

The official record: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's restricted cash?
Kodiak Sciences Inc (KOD) reported restricted cash of $6.18M in Q1 2026.
How has Kodiak Sciences Inc's restricted cash changed year-over-year?
Kodiak Sciences Inc's restricted cash decreased by 0.0% year-over-year, from $6.18M to $6.18M.
What is the long-term trend for Kodiak Sciences Inc's restricted cash?
Over 5 years (2020 to 2025), Kodiak Sciences Inc's restricted cash has grown at a -0.4% compound annual growth rate (CAGR), from $6.32M to $6.18M.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.